recurrence. Such a prognostic index, while not intended to improve candidate selection before LT, would help identify candidates for adjuvant therapies and determine appropriate post-LT HCC surveillance, which is currently not standardized and varies widely in practice across LT centers. 2, 4 Researchers in a large multicenter study recently developed and validated the Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score incorporating 3 variables that independently predicted post-LT HCC recurrence: microvascular invasion, α-fetoprotein (AFP) at LT, and the sum of the largest viable tumor diameter and number of viable tumors on explant 11 (Table 1) . Among patients with HCC meeting Milan criteria before LT, RETREAT was able to stratify 5-year post-LT tumor recurrence risk from less than 3% for those with a score of 0 to greater than 75% for a score of 5 or greater. A potential limitation of this study is the significantly higher HCC recurrence rate in the validation cohort compared with the development cohort, despite including only patients with HCC meeting Milan criteria prior to LT.
Since the RETREAT score was derived from high-volume LT centers, the validity of the RETREAT score when applied on a broader scale has not been tested. The methods used to create the RETREAT score have previously been described. 11 An individual's RETREAT score (range 0-8) is calculated by adding the assigned points for each of the 3 components (Table 1 
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To 
| Statistical analysis and validation of the RETREAT score
Clinical and tumor characteristics were described with medians and interquartile ranges (IQRs) or frequency and percentages.
Characteristics were compared by RETREAT score with the use of Kruskal-Wallis or χ 2 tests to assess statistical differences. Observed HCC recurrence and post-LT survival probabilities and 95% confidence intervals (CIs) were estimated at 1 and 3 years by using the Kaplan-Meier method and compared by RETREAT score by using the log-rank test. The ability of the RETREAT score model to discriminate between events and nonevents, for the outcome of HCC recurrence, was assessed by using the overall C-index 13 with bootstrap 95% CIs.
For the primary outcome, HCC recurrence, net reclassification index 14 evaluated improvement in model performance by quantifying the proportion of correct risk reclassification when using RETREAT score versus explant-based Milan criteria to predict risk. Net reclassification improvement was evaluated at 1 and 3 years post-LT by using a priori recurrence risk categories (<5%, 5% to <10%, 10% to <20%, and ≥20%). Correct risk reclassification occurred when RETREAT score-predicted probabilities reclassified patients with recurrence into higher risk categories and patients without recurrence into lower risk categories compared with estimates by explant Milan criteria.
| RESULTS
| Patient and center characteristics
Among The baseline characteristics of the final study cohort are summarized in Table 2 . The median age at listing with MELD exception was 60 years (IQR 56-63) and 76.7% were men. The most common race/ ethnicities were white (69.0%), Hispanic (13.4%), African American (9.3%), and Asian (7.1%). Hepatitis C was the most common cause of liver disease (62.8%), followed by nonalcoholic fatty liver disease (8.0%), alcoholic liver disease (7.3%), and hepatitis B (5.5%). At the 
| Tumor characteristics at transplantation and RETREAT score distribution
In the explant, the tumors showed complete necrosis with no viable tumor as a result of LRT in 30.4%, were within Milan criteria in 55.4%, and were understaged to beyond Milan criteria in 14.2%.
Macrovascular invasion was found in 1.7%. Among patients with viable tumors in the explant, most had either well-differentiated (31.8%) or moderately differentiated HCC (59.0%), while only 9.2% had poorly differentiated tumor grade.
Tumor characteristics at the time of LT used to calculate the RETREAT score are shown in RETREAT score of 0, 8.4% with score of 3, and 29.0% for a score of 5 or higher (P < .001) ( Figure 3 ).
We also sought to determine if RETREAT score was associated Median time from HCC recurrence to death was 4.5 months (IQR 0.5-9.9, n = 99) and was similar across all RETREAT scores (P = .98). We also found no statistically significant differences in etiology of liver disease among the low-and high-risk HCC recurrence groups. Improvement was primarily among patients with HCC recurrence, where 27% were correctly assigned to a higher risk category and 10% were incorrectly assigned to a lower risk category (net relative improvement 17%, P = .001). Among nonevents, 8% were correctly reclassified to a lower risk category and 7% were incorrectly assigned to a higher risk category, resulting in no change in risk classification among nonevents (net relative improvement 1%, P = .32). RETREAT also improved risk reclassification at 3 years post-LT (overall net reclassification index 0.28, P < .001).
| RETREAT score vs Milan criteria
| DISCUSSION
The present study using the UNOS database has provided further evidence supporting the RETREAT score as a powerful prognostic index for patients undergoing LT for HCC within Milan criteria. The present study included 3 times the number of patients compared with the original study. 11 We found that increasing RETREAT scores in the UNOS database not only predicted increased post-LT recurrence but also worse survival. The RETREAT score is strongly associated with the risk of HCC recurrence after LT, from 1.6% at 3 years for a score Another important observation of the present study is that increasing RETREAT score is associated with a shorter time to HCC recurrence. Patients with a high RETREAT score of 4 or higher recurred 11 months after LT and on average 3 months faster than patients with a low RETREAT score of 0 to 1. Early HCC recurrence has been shown to be a poor prognostic factor. In the study by Sapisochin et al, 9 the 1 year survival (postrecurrence) was only 30% in patients with early HCC recurrence compared with 60% in those who had recurrence more than 1 year after LT. Similarly, Bodzin et al 10 showed the worst survival in patients with HCC recurrence less than 7 months after LT, followed by those who had HCC recurrence between 7 and 15 months after LT. Our finding that higher RETREAT score is associated with early tumor recurrence continues to strengthen the notion that early tumor recurrence is an important signal of poor tumor biology. While time from HCC recurrence to death was similar across RETREAT scores in the present study, this may be due to short follow-up after HCC recurrence, because less than two-thirds with HCC recurrence in UNOS had died at the end of study follow-up compared with 82% in the Bodzin et al study 10 and 80% in the Sapisochin et al study. 9 The distribution of RETREAT scores in UNOS was similar to those scores seen in the original development cohort, 11 with 23% having a RETREAT score of 0 (AFP ≤20 and no viable tumor or microvascular invasion on explant), 33% having a score of 1, and 12% having a score of 4 or higher. Given that some patients with HCC recurrence after LT are eligible for resection or ablation and can achieve long-term survival after these treatments, 9 tumor surveillance after LT remains useful. We believe that the RETREAT score helps determine whether HCC surveillance after LT is warranted. We have previously proposed guidelines for post-LT HCC surveillance strategy 11 that have been implemented at our institution (Table 4) The RETREAT score not only identifies candidates at high risk for HCC recurrence but also provides a reference for the expected incidence of HCC recurrence, both of which are extremely important to properly design and to select appropriate candidates for future clinical trials.
Those with a high risk for HCC recurrence based on a RETREAT score of at least 4 should be considered for enrollment into clinical trials with adjuvant therapies given shortly after LT to reduce post-LT HCC recurrence risk, rather than waiting to treat patients after they have developed recurrent HCC.
Obviously, a priority for research in this field is to further improve candidate selection to limit HCC recurrence after LT. Some progress has been made by incorporating AFP [23] [24] [25] and response to LRT and treating HCC, guided by an accurate and validated prognostic scoring system, remains an important focus of future research.
There are several limitations of the present study. We excluded nearly 20% of the UNOS cohort due to missing information on AFP at the time of LT. Some potential risk factors for HCC recurrence, including neutrophil:lymphocyte ratio 35 and response to LRT, were not available in the UNOS database. However, RETREAT in part accounts for the effects of preoperative LRT as those with no viable tumor(s)
as a result of complete response to LRT receive no added RETREAT points, reflecting a low risk for HCC recurrence. 36, 37 In addition, hepatitis C treatment history was not available in the UNOS database, and thus we could not assess the potential effects of treatment with direct-acting antivirals on posttransplantation HCC recurrence. 38, 39 Because the study period predates the widespread use of Interferonfree therapy, we do not believe that there is a significant impact of In conclusion, RETREAT is a simple and novel risk score for predicting individual risk for HCC recurrence after LT. This study validated RETREAT as a prognostic scoring system when applied on a broader scale using the UNOS database. RETREAT also outperformed the Milan criteria in predicting HCC recurrence. This prognostic score may help standardize post-LT HCC surveillance strategies, provide a framework for tumor staging and risk stratification, and select appropriate candidates for adjuvant therapies.
